Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

The S&P 500 and Nasdaq climbed due to positive earnings reports, despite uncertainties surrounding Trump's policies and ...

Eli Lilly has said it is seeking permission to build ... be more than €400 million ($445 million), and could create 300 jobs at the plant itself, with another 500 positions required while ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Trump's tariff plans are squarely in focus for investors amid another busy week on Wall Street that will include quarterly reports from more than 100 S&P 500 companies and the January jobs report.

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...